Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Citigroup Inc. from $12.00 to $9.00. They now have a "neutral" rating on the stock.
Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at Piper Sandler from $140.00 to $72.00. They now have an "overweight" rating on the stock.
Arcturus Therapeutics (NASDAQ:ARCT) had its price target lowered by analysts at HC Wainwright from $12.00 to $9.00. They now have a "neutral" rating on the stock.
Arcturus Therapeutics Holdings Inc (ARCT) Q3 2025 Earnings Call Highlights: Navigating ... [Yahoo! Finance]